Introduction
Anaplastic large cell lymphomas (ALCLs) are a group of T-cell lymphomas composed of anaplastic large lymphoid cells which show diffuse CD30 positivity. It includes three entities, namely anaplastic lymphoma kinase positive, ALCL (ALK+ ALCL), ALK-negative ALCL (ALK− ALCL), and primary cutaneous ALCL (PC-ALCL). [1] [2] [3] ALCL should be distinguished from other lymphomas with anaplastic features which may also show CD30 expression, like diffuse large B-cell lymphoma (DLBCL), classical Hodgkin lymphoma, and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). In this single institutional study of eight cases, we analyze the clinicopathological features and immunohistochemical (IHC) profile of ALCL with emphasis on diagnostic pitfalls.
Materials and Methods
All cases diagnosed as ALCL over a period of 4 years in our institution (2011) (2012) (2013) (2014) , were included in the study. Hematoxylin and eosin sections and IHC sections were reviewed. All cases were stained with CD45, CD30, ALK-1, CD20, PAX5, CD15, epithelial membrane antigen (EMA), Epstein-Barr virus (latent membrane protein-1) and Ki-67 using standard IHC protocols. Fluorescent in situ hybridization (FISH) for ALK translocation t(2;5)(p23;q35) was carried out using Vysis ALK dual color LSI break apart FISH probe.
Results
Of a total of 246 cases of non-Hodgkin lymphoma (NHL) diagnosed over a period of 4 years, eight cases (3.3%) were categorized as ALCL. Of these, four were ALK+ ALCL, and there were two cases each of ALK− ALCL and PC-ALCL. The clinical features and histopathological findings are summarized in Table 1 . The age range was 15-72 years with an equal sex distribution in all the subtypes. B-symptoms were present in four cases, three of which were ALK+ ALCL. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. Leukemia and Lymphoma ORIGINAL ARTICLE 1 year, and 2 years 9 months, respectively. Two patients; one ALK+ ALCL (Case number 4) and one ALK− ALCL (Case number 5), expired at diagnosis, and the remaining three were lost to follow-up.
Discussion
The rarity of ALCL was highlighted in our study which showed it to comprise 3.3% (8/246) of all NHL. A clinical evaluation of 1378 cases of NHL by International NHL Classification Project found ALCL to be comprising 2.4%. [4] The clinical profile of our patients was similar to that described in literature. ALK+ ALCL mostly occurs in the first three decades of life with the male:female ratio ranging from 1.5 and 6.5. [1] This lymphoma is aggressive and frequently presents as Stage III-IV disease with systemic symptoms and extranodal involvement. [1] The frequency of BM involvement is 11%. Only one case of ALK+ ALCL in our series had BM involvement. ALK− ALCL occurs in older patients, peak age of incidence being in the sixth decade of life, with a lower male predominance when compared to ALK+ ALCL. Advanced-stage disease and B-symptoms are relatively less common. [2, 5] Primary cutaneous CD30-positive T-cell lymphoproliferative disorders include PC-ALCL and lymphomatoid papulosis (LyP). The median age at diagnosis for PC-ALCL is 60 years with a male:female ratio of 2-3:1. [3, 6] Common sites of involvement are the face, trunk, extremities, and buttocks. They commonly present with solitary nodules that may ulcerate. In 20% of cases, the lesions are multiple while in 10% cases there may be regional lymph node involvement. [3, 6] Histologically, all types of ALCL are characterized by sheets of large pleomorphic cells with a variable proportion of "hallmark" cells showing typical horseshoe-shaped nuclei. In ALK+ ALCL, morphological patterns that have been recognized are: (1) Common pattern (60%); (2) lymphohistiocytic pattern (10%); (3) small cell pattern (5-10%); (4) Hodgkin-like pattern (3%); and (5) composite pattern (15%). [1, 4] One case of ALK+ ALCL in our series showed nodular sclerosis Hodgkin-like pattern. The rest showed "common pattern." The histology of ALK− ALCL shows a similar morphologic spectrum. [2, 4] PC-ALCL shows nonepidermotropic infiltrates of anaplastic cells with a variable number of inflammatory cells in the background which are especially prominent in ulcerated lesions. To differentiate such cases from LyP features like lesions limited to an anatomical region and infiltration into subcutaneous tissue favor a diagnosis of PC-ALCL. [7] The defining feature of all types of ALCL is strong and diffuses CD30 staining in more than 75% of tumor cells. All eight cases in our series had a uniform and intense CD30 staining. Positivity for CD30 is not specific for ALCL and can be expressed by HRS cells and a subset of B-and T-cell lymphomas. [4] However, the CD30 immunostain is generally less intense in CD30+ PTCL-NOS and DLBCL and is often seen only in a fraction of tumor cells. ALCL usually demonstrate an aberrant T phenotype, with frequent loss of T-cell markers. Null cell ALCL by IHC can usually be proven to be lymphoma of T-cell origin with clonal T-cell receptor rearrangements. [4] In our series, aberrant T-cell antigen loss was a frequent finding. A diagnostic pitfall is negative or weak staining for LCA in some cases of ALCL. [8] One case of PC-ALCL was LCA negative with loss of T-cell antigens and initially misdiagnosed as melanoma at another institute. Hence in suspected cases, CD30 should always be included in the initial IHC panel. In certain situations, like Case number 4 in our study, which was a treated case of carcinoma esophagus, metastatic carcinoma may enter the histological differential diagnosis. It is preferable to use cytokeratin immunostain than EMA for this purpose as ALCL can be EMA positive. [4] EMA expression is more frequent in ALK+ than ALK− ALCL (83% vs. 43%). [5] In histologically suspected cases which are a CD30 positive, further evaluation with markers for T-cells (CD2, CD3, CD5), B-cells (CD20, PAX5), Hodgkin lymphoma (CD15, PAX5) and ALCL (ALK-1) is required. To distinguish PC-ALCL from systemic ALCL with secondary skin involvement, EMA can be helpful, which is usually negative in the former. [7] Feature which differentiates ALK− ALCL from PTCL-NOS is weak and heterogeneous staining of CD30, consistent expression of T-cell markers and EMA negativity in the latter. [5] Systemic ALK+ ALCL show t(2;5)(p23;q35) in 84% cases. Variant translocations also occur, albeit with a much lower frequency. [9] Translocation t(2;5) results in a nuclear and diffuse cytoplasmic staining for ALK-1 on IHC. All the four ALK+ ALCL cases in our series showed nuclear and diffuse cytoplasmic staining and two of these who were tested for t(2;5) by FISH were positive. Variant translocations can produce cytoplasmic, membranous or nuclear staining patterns. [1] CHOP chemotherapy regimen remains the standard of care in primary systemic ALCL. The addition of etoposide to the standard CHOP regimen is an important consideration for young patients with ALK+ ALCL. [10] Immunologic strategies with anti-CD30 agent brentuximab vedotin and ALK inhibitor crizotinib have also been used. Solitary or localized PC-ALCL is best treated with radiation therapy or surgical excision.
Five year overall survival (OS) rates for ALK+ ALCL have ranged from 70% to 93% and that of ALK− ALCL from 15% to 49%. [5] PC-ALCL has a very high OS of 90% at 10 years. [3] Two patients of ALK+ ALCL and one of PC-ALCL who were given CHOP therapy showed good response to treatment and were in clinical remission at their last follow-up.
Conclusions
The clinical and histopathological findings of our study are commensurate with that recorded in literature. LCA negativity and aberrant T-cell antigen loss are potential diagnostic pitfalls. However, a diligent search for hallmark cells with the inclusion of CD30 and at least two T-cell markers in the initial IHC panel will clinch the diagnosis in most cases.
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